FindTrial
Sign In

Clinical study on the antagonism of Liandan mixture to oxidative stress in the improvement of hepatic cholestatic fibrosis in infants

Clinical study on the antagonism of Liandan mixture to oxidative stress in the improvement of hepatic cholestatic fibrosis in infants

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041352
Enrollment
Unknown
Registered
2020-12-24
Start date
2020-12-25
Completion date
Unknown
Last updated
2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholestasis-induced liver fibrosis

Interventions

treatment group:Ursodeoxycholic acid and Choleric mixture
observation group:ursodesoxycholic acid

Sponsors

Wuhan Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: 1. Subjects aged 1-12 months; 2. Subjects meeting the diagnostic criteria of TCM and Western medicine; 3. Subjects with parents' consent and informed consent.

Exclusion criteria

Exclusion criteria: 1. Children are highly suspected of bile duct malformation diseases such as biliary atresia, choledochal cyst and choledochal dilatation; 2. Patients with liver failure and other critical conditions in the course of disease who need intensive care rescue; 3. Patients who cannot cooperate with treatment and have incomplete data.

Design outcomes

Primary

MeasureTime frame
PLT;ALT;AST;ALP;TBA;TBIL;DBIL;GGT;HA;P-III-P;IV-C;LN;SOD;GSH;—

Countries

China

Contacts

Public ContactSuqi Yan

Hubei University of traditional Chinese Medicine

1535229418@qq.com+86 13657270856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026